Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Castle Biosciences, Inc.

Castle Biosciences develops innovative molecular diagnostics aimed at delivering personalized information to inform healthcare decisions. Their tests focus on melanoma metastasis risk and mental health medication profiles, among other areas.

msh id	COM:CASTLEBIOSCIENCES
symbol	CSTL
name	Castle Biosciences, Inc.
homepage url	https://castlebiosciences.com
country	US
sector	Healthcare
industry	Medical - Diagnostics & Research
market	STOCKS
employee count	638
crunchbase url	-
linkedin url	-
founders	-

market cap	482.57M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.22
growth cost of revenue	0.31
growth depreciation and amortization	-0.18
growth ebitda	0.17
growth ebitda ratio	0.41
growth eps	1
growth eps diluted	1
growth general and administrative expenses	-
growth gross profit	0.43
growth gross profit ratio	0.02

COM:CASTLEBIOSCIENCES

Castle Biosciences

Last Close

28.45

21/11 21:00

Market Cap

482.57M

Beta: -

Volume Today

419.43K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	287.77M
cost of revenue	287.77M
depreciation and amortization	12.33M
ebitda	-55.65M
ebitda ratio	-0.25
eps	-2.14
eps diluted	-2.14
operating expenses	232.21M
operating income	-67.98M
operating income ratio	-0.31

accounts receivables	-14.93M
capital expenditure	-13.62M
cash at beginning of period	122.95M
cash at end of period	98.84M
inventory	7.94M
working capital ttm	243.3M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-